Takeda Pharmaceutical (TAK) Change in Receivables (2018 - 2026)

Takeda Pharmaceutical's Change in Receivables history runs 9 years deep, the most recent figure standing at -$621.8 million for Q1 2026.

• On a quarterly basis, Change in Receivables fell 584.76% year-over-year to -$621.8 million in Q1 2026; TTM through Mar 2026 was -$427.1 million, a 11.97% decrease from a year earlier, with the FY2026 full-year figure at -$466.1 million, down 20.43% from the prior year.
• Change in Receivables eased to -$621.8 million in Q1 2026 per TAK's latest filing, from -$71.1 million in the prior quarter.
• Across five years, Change in Receivables topped out at $516.1 million in Q1 2023 and bottomed at -$659.4 million in Q2 2023.
• The 5-year median for Change in Receivables is $83.4 million (2024), against an average of $11.2 million.
• Across the five-year window, Change in Receivables jumped 208.35% in 2025 and sank 584.76% in 2026, its largest moves.
• Year by year, Change in Receivables stood at $90.4 million in 2022, then gained by 6.93% to $96.7 million in 2023, then declined by 13.75% to $83.4 million in 2024, then sank by 185.24% to -$71.1 million in 2025, then plunged by 775.04% to -$621.8 million in 2026.
• Per Business Quant, the three latest TAK Change in Receivables figures stand at -$621.8 million (Q1 2026), -$71.1 million (Q4 2025), and -$66.5 million (Q3 2025).